We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

THERMO FISHER SCIENTIFIC

Thermo Fisher Scientific provides analytical instruments, lab equipment, specialty diagnostics, reagents and integrat... read more Featured Products: More products

Download Mobile App




Serum Mir‐22 Prognostic Marker Explored for Acute Myeloid Leukemia

By LabMedica International staff writers
Posted on 25 Jun 2020
Acute myeloid leukemia (AML) is an aggressive hematopoietic stem cell malignancy that is characterized by the clonal proliferation of myeloid precursors. More...
Abnormal accumulation of leukemic blasts in the bone marrow, blood, and other tissues results in significant reductions of normal blood cells.

MicroRNAs (miRNAs) are small (19‐25 nucleotide), noncoding RNAs that control the gene expression at the post‐transcriptional level, leading to target mRNAs degradation or translational inhibition. Increasing evidence has demonstrated that miRNA dysregulation is associated with the initiation and progression of cancer.

Scientists at the Panyu Central Hospital (Guangzhou, China) enrolled a total of 124 patients with newly diagnosed AML and 60 healthy individuals as controls in a study. Serum samples were collected and stored. Total RNA was isolated from serum with the miRNeasy Serum/Plasma kit (Qiagen, Hilden, Germany). The RNA concentration was measured with a NanoDrop 2000 spectrophotometer (Thermo Fisher Scientific, Waltham, MA, USA).

Cel‐miR‐39 was used as the spiked‐in control. The cDNA was reverse‐transcribed from total RNA using the TaqMan MicroRNA Reverse Transcription Kit (Applied Biosystems, Foster City, CA, USA). The amplification of cDNAs was performed on the Applied Biosystems 7500 Real‐Time PCR system. The relative serum miR‐22 expression levels were normalized to cel‐miR‐39 and calculated by the 2–ΔΔC t method.

The investigators reported that the serum miR‐22 expression was significantly downregulated in AML subjects compared to healthy controls. Serum miR‐22 levels were lowest in AML patients with M4/M5 subtypes, and low serum miR‐22 expression occurred more frequently in AML patients with higher white blood cell counts or poor cytogenetic risk. Receiver operating characteristic (ROC) analysis revealed that serum miR‐22 well differentiated AML cases from healthy controls. In addition, serum miR‐22 downregulation was closely associated with worse clinical features and shorter survival. Low serum miR‐22 expression was confirmed to be an independent predictor for overall survival and relapse‐free survival in AML patients. Moreover, the expression level of serum miR‐22 was dramatically increased following treatment. In addition, serum miR‐22 levels were significantly higher in AML patients achieving complete remission (CR) than those without CR.

The authors concluded they had demonstrated that the serum miR‐22 expression is markedly downregulated in AML. In addition, downregulation of serum miR‐22 is significantly associated with aggressive clinical variables and poor prognosis of AML. Therefore, serum miR‐22 might serve as a promising prognostic biomarker for AML. The study was published on June 12, 2020 in the Journal of Clinical Laboratory Analysis.




Gold Member
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Silver Member
Quality Control Material
Multichem ID-B
New
Gold Member
Serological Pipets
INTEGRA Serological Pipets
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.